Next-generation sequencing and detection of minimal residual disease in acute myeloid leukemia: Ready for clinical practice?
Menée sur 76 patients atteints d'une leucémie myéloïde aiguë, cette étude évalue l'intérêt d'une technique de séquençage génomique profond pour identifier la présence persistante de cellules leucémiques après un traitement d'induction
Acute myeloid leukemia (AML) represents a heterogeneous disease, both with respect to molecular pathogenesis and clinical outcome. Although dose-intensive chemotherapy and allogeneic stem cell transplantation have improved outcomes in AML, there remains significant heterogeneity in clinical outcome such that approximately 20% of patients are cured with existing therapies, 20% have therapy-refractory disease from the time of diagnosis, and 50% relapse and die from refractory disease after an initial response to leukemia therapy.1- 4 The challenge is how to best determine prognosis and identify which patients will have a substantive chance of cure, and which patients will likely relapse or present with refractory disease. Current standard of care uses clinical, cytogenetic, and molecular factors for risk stratification; however, there remains a pressing need for better approaches to prognostication in AML.
JAMA , éditorial, 2014